These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 21859732)

  • 1. Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARA.
    Schnittger S; Bacher U; Haferlach C; Kern W; Alpermann T; Haferlach T
    Haematologica; 2011 Dec; 96(12):1799-807. PubMed ID: 21859732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study.
    Lucena-Araujo AR; Kim HT; Jacomo RH; Melo RA; Bittencourt R; Pasquini R; Pagnano K; Fagundes EM; Chauffaille Mde L; Chiattone CS; Lima AS; Ruiz-Argüelles G; Undurraga MS; Martinez L; Kwaan HC; Gallagher R; Niemeyer CM; Schrier SL; Tallman MS; Grimwade D; Ganser A; Berliner N; Ribeiro RC; Lo-Coco F; Löwenberg B; Sanz MA; Rego EM
    Ann Hematol; 2014 Dec; 93(12):2001-10. PubMed ID: 24981688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between FLT3-ITD status and clinical, cellular and molecular profiles in promyelocytic acute leukemias.
    Souza Melo CP; Campos CB; Dutra ÁP; Neto JC; Fenelon AJ; Neto AH; Carbone EK; Pianovski MA; Ferreira AC; Assumpcão JG
    Leuk Res; 2015 Feb; 39(2):131-7. PubMed ID: 25530565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytogenetic and FMS-like tyrosine kinase 3 mutation analyses in acute promyelocytic leukemia patients.
    Yaghmaie M; Alimoghaddam K; Mozdarani H; Ghavamzadeh A; Hajhashemi M; Aznab M; Ghaffari SH
    Iran Biomed J; 2012; 16(1):10-7. PubMed ID: 22562027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients.
    Chillón MC; Santamaría C; García-Sanz R; Balanzategui A; Sarasquete ME; Alcoceba M; Marín L; Caballero MD; Vidriales MB; Ramos F; Bernal T; Díaz-Mediavilla J; García de Coca A; Peñarrubia MJ; Queizán JA; Giraldo P; San Miguel JF; González M
    Haematologica; 2010 May; 95(5):745-51. PubMed ID: 20133893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia.
    Gallagher RE; Moser BK; Racevskis J; Poiré X; Bloomfield CD; Carroll AJ; Ketterling RP; Roulston D; Schachter-Tokarz E; Zhou DC; Chen IM; Harvey R; Koval G; Sher DA; Feusner JH; Tallman MS; Larson RA; Powell BL; Appelbaum FR; Paietta E; Willman CL; Stock W
    Blood; 2012 Sep; 120(10):2098-108. PubMed ID: 22734072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. All-trans Retinoic Acid, Arsenic Trioxide, and Anthracycline-based Chemotherapy Improves Outcome in Newly Diagnosed Acute Promyelocytic Leukemia Regardless of FLT3-ITD Mutation Status.
    Xu LW; Su YZ; Tao HF
    Curr Med Sci; 2021 Jun; 41(3):491-497. PubMed ID: 34169421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy.
    Cicconi L; Divona M; Ciardi C; Ottone T; Ferrantini A; Lavorgna S; Alfonso V; Paoloni F; Piciocchi A; Avvisati G; Ferrara F; Di Bona E; Albano F; Breccia M; Cerqui E; Sborgia M; Kropp MG; Santoro A; Levis A; Sica S; Amadori S; Voso MT; Mandelli F; Lo-Coco F
    Leukemia; 2016 Oct; 30(10):1987-1992. PubMed ID: 27133819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.
    Cervera J; Montesinos P; Hernández-Rivas JM; Calasanz MJ; Aventín A; Ferro MT; Luño E; Sánchez J; Vellenga E; Rayón C; Milone G; de la Serna J; Rivas C; González JD; Tormo M; Amutio E; González M; Brunet S; Lowenberg B; Sanz MA
    Haematologica; 2010 Mar; 95(3):424-31. PubMed ID: 19903674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy.
    Barragán E; Montesinos P; Camos M; González M; Calasanz MJ; Román-Gómez J; Gómez-Casares MT; Ayala R; López J; Fuster Ó; Colomer D; Chillón C; Larrayoz MJ; Sánchez-Godoy P; González-Campos J; Manso F; Amador ML; Vellenga E; Lowenberg B; Sanz MA; ;
    Haematologica; 2011 Oct; 96(10):1470-7. PubMed ID: 21685470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype.
    Poiré X; Moser BK; Gallagher RE; Laumann K; Bloomfield CD; Powell BL; Koval G; Gulati K; Holowka N; Larson RA; Tallman MS; Appelbaum FR; Sher D; Willman C; Paietta E; Stock W
    Leuk Lymphoma; 2014 Jul; 55(7):1523-32. PubMed ID: 24160850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prevalence and clinical significance of FLT3 mutations in acute promyelocytic leukemia].
    Xue MX; Qiu HY; Feng YF; Zhu ZL; Chang WR; Liang JY; Chen SN; Cen JN; Xue YQ; Liu YJ; Sun AN; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2008 Nov; 29(11):757-61. PubMed ID: 19176014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia.
    Gale RE; Hills R; Pizzey AR; Kottaridis PD; Swirsky D; Gilkes AF; Nugent E; Mills KI; Wheatley K; Solomon E; Burnett AK; Linch DC; Grimwade D;
    Blood; 2005 Dec; 106(12):3768-76. PubMed ID: 16105978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inferior prognostic outcome in acute promyelocytic leukemia with alterations of FLT3 gene.
    Yoo SJ; Park CJ; Jang S; Seo EJ; Lee KH; Chi HS
    Leuk Lymphoma; 2006 Sep; 47(9):1788-93. PubMed ID: 17064989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Internal tandem duplication and Asp835 mutations of the FMS-like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia.
    Shih LY; Kuo MC; Liang DC; Huang CF; Lin TL; Wu JH; Wang PN; Dunn P; Lai CL
    Cancer; 2003 Sep; 98(6):1206-16. PubMed ID: 12973844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of FLT3 internal tandem duplications on Indian acute promyelocytic leukemia patients: prognostic implications.
    Hasan SK; Sazawal S; Dutta P; Pillai LS; Kumar B; Chaubey R; Kumar R; Saxena R
    Hematology; 2007 Apr; 12(2):99-101. PubMed ID: 17454189
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Esnault C; Rahmé R; Rice KL; Berthier C; Gaillard C; Quentin S; Maubert AL; Kogan S; de Thé H
    Blood; 2019 Mar; 133(13):1495-1506. PubMed ID: 30674471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new chromosome translocation t(7;16)(q31,q22) change during an acute promyelocytic leukemia relapse.
    Cao Y; Yuan R; Wang Y; Chen R; Huang M; Zhou J
    Cytogenet Genome Res; 2013; 141(1):70-4. PubMed ID: 23651981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors of patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide-based frontline therapy.
    Lou Y; Ma Y; Suo S; Ni W; Wang Y; Pan H; Tong H; Qian W; Meng H; Mai W; Huang J; Yu W; Wei J; Mao L; Jin J
    Leuk Res; 2015 Sep; 39(9):938-44. PubMed ID: 26183877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Significance of bcr-1 and bcr-3 Isoforms of PML-RARA and FLT3-ITD in Patients With Acute Promyelocytic Leukemia.
    Rasekh EO; Elsayed GM; Madney Y; El Gammal MM
    Clin Lymphoma Myeloma Leuk; 2020 Mar; 20(3):156-167. PubMed ID: 32033928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.